Patients Derived Organoids in Ovarian Cancer

Among cancer models, patients derived organoids (PDOs) best reproduce tumor's tissue architecture, intratumor heterogeneity and are able to mimic in vivo patients' drugs response. For these reasons, it has been designed a study to assess the feasibility of PDOs immune cells co-culture in OC patients and the concordance between ex vivo sensitivity and in vivo treatment response. If proven effective and reliable, PDOs could be introduced into clinical practice as empirical predictor of patients' response to antineoplastic drugs.

Trial Details

NCT ID
NCT06085404
Phase
NA
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Blood sample
Locations (sample)
  • Roma, Italy|44.99364,11.10642

Key Eligibility Criteria

  • Preoperative clinical, serological and radiologic suspicion of International Federation of Gynecology and Obstetrics (FIGO) stage IIIC or greater o…
  • Histologic diagnoses of epithelial ovarian cancer at frozen section
  • Age \>18 and years;
  • Estimated life expectancy of at least 4 weeks;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →